The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company offered 1.5 million more shares than...read more
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $120 million by offering 7.5 million shares at a price range...read more
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Biomea is focused on the development of irreversible small...read more
US IPO Weekly Recap: Coinbase’s direct listing headlines a 9 IPO week
The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Preclinical cancer biotech Biomea Fusion prices upsized IPO at $17 high end
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company offered 1.5 million more shares than...read more
Preclinical cancer biotech Biomea Fusion sets terms for $120 million IPO
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $120 million by offering 7.5 million shares at a price range...read more
Preclinical cancer biotech Biomea Fusion files for a $100 million IPO
Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Biomea is focused on the development of irreversible small...read more